N-Myristoyltransferase 1 (NMT1) is a ubiquitously expressed enzyme that catalyzes the transfer of myristate, a 14-carbon fatty acid, to the N-terminal glycine residue of target proteins—a post-translational modification critical for membrane association, protein-protein interactions, and cellular localization. This process regulates diverse biological processes, including signal transduction, apoptosis, and oncogenesis. Dysregulation of NMT1 has been implicated in cancer progression, neurodegenerative diseases, and viral pathogenesis, as many oncoproteins, viral proteins, and signaling molecules rely on N-myristoylation for functionality.
NMT1 antibodies are essential tools for studying the expression, localization, and activity of NMT1 in both physiological and pathological contexts. They enable detection of NMT1 in techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding research into its role in diseases such as colorectal cancer, glioblastoma, and Alzheimer's disease. Additionally, these antibodies support drug discovery efforts targeting NMT1. as small-molecule inhibitors are being explored for cancer and antiviral therapies. Commercial NMT1 antibodies are typically validated for specificity against conserved epitopes, though cross-reactivity with NMT2 (a closely related isoform) must be considered. Recent studies also highlight NMT1's potential as a biomarker for therapeutic resistance, emphasizing its clinical relevance. Overall, NMT1 antibodies are pivotal in unraveling the enzyme's multifaceted roles and advancing translational research. (299 words)